Aqilion focuses on diseases caused by chronic inflammation and dysfunctional immunological reactions

We explore novel scientific findings describing the biology behind the diseases and focus on developing new innovative treatments. Our mission is clear, we identify opportunities based on solid research resting on a firm biological foundation offering both clinical relevance and patient benefit.

Sarah Fredriksson, CEO, presents Aqilion:

Aqilion is a biotech company developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions. The company is active in early phases of drug discovery, from idea stage to early clinical development.

Main focus is to  develop and refine Aqilion’s project portfolio within chronic inflammation and immunology.

Subscribe

Read more about our Protection of your personal data.